Try our beta test site
53 studies found for:    Open Studies | "Sarcoma, Ewing's"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting TK216 in Patients With Relapsed or Refractory Ewing Sarcoma
Condition: Sarcoma, Ewing
Intervention: Drug: TK216
2 Recruiting Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma
Condition: Ewing's Sarcoma
Interventions: Drug: Standard treatment (as per protocol ISG SSG III);   Drug: Intensified chemotherapy
3 Recruiting Randomized Phase IIb Trial of Vigil Versus Gemcitabine + Docetaxel for Ewing's Sarcoma
Condition: Ewing's Sarcoma
Interventions: Biological: Vigil;   Drug: gemcitabine and docetaxel
4 Recruiting Study in Localized and Disseminated Ewing Sarcoma
Condition: Ewing's Sarcoma
Interventions: Drug: Zoledronic acid;   Drug: Busulfan;   Drug: Treosulfan
5 Recruiting First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years
Condition: Ewing Sarcoma Family of Tumors
Interventions: Drug: VDC-IE x2;   Drug: VDC-IE;   Drug: TEMIRI;   Drug: Consolidation BuMel;   Drug: Maintenance;   Procedure: Local treatment by surgery;   Radiation: Local treatment by radiotherapy
6 Available Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma
Condition: Ewing Sarcoma
Intervention: Drug: Ganitumab
7 Recruiting Phase I Study of Olaprib and Temozolomide for Ewings Sarcoma
Condition: Ewing Sarcoma
Interventions: Drug: Olaparib;   Drug: Temozolomide;   Drug: Irinotecan
8 Recruiting Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma
Condition: Ewing's Sarcoma
Intervention: Biological: pbi-shRNA™ EWS/FLI1 Type 1 LPX
9 Recruiting ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients With Previously Treated, Incurable Ewing Sarcoma
Condition: Ewing Sarcoma
Interventions: Drug: niraparib;   Drug: Temozolomide;   Drug: Irinotecan
10 Recruiting Protocol for the Treatment of Metastatic Ewing Sarcoma
Condition: Ewing's Sarcoma (ES)
Interventions: Drug: TEMIRI;   Drug: ADM;   Drug: IFO;   Drug: CYC;   Drug: ETO;   Drug: BUMEL;   Drug: VIN
11 Recruiting Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma
Condition: Newly Diagnosed Ewing Sarcoma
Interventions: Drug: Cyclophosphamide;   Device: Doxorubicin;   Drug: Vincristine;   Device: Ifosfamide;   Drug: Etoposide;   Procedure: Surgery;   Radiation: Radiation Therapy*;   Drug: Temozolomide;   Drug: Irinotecan
12 Recruiting Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors
Conditions: Ewing Sarcoma;   Rhabdomyosarcoma;   Wilms Tumor
Intervention: Radiation: Stereotactic Body Radiotherapy (SBRT)
13 Recruiting Collecting and Storing Biological Samples From Patients With Ewing Sarcoma
Conditions: Askin Tumor;   Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Intervention: Other: laboratory biomarker analysis
14 Recruiting Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Conditions: Metastatic Ewing Sarcoma;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Bone Marrow;   Metastatic Malignant Neoplasm in the Lung;   Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone;   Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
Interventions: Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Radiation: External Beam Radiation Therapy;   Biological: Ganitumab;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Radiation: Stereotactic Radiosurgery;   Procedure: Therapeutic Surgical Procedure;   Drug: Vincristine Sulfate
15 Recruiting A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma
Condition: Relapsed or Refractory Medulloblastoma (MB) (Part A: Also Include Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS))
Interventions: Drug: TB-403 20mg/kg;   Drug: TB-403 50mg/kg;   Drug: TB-403 100mg/kg;   Drug: TB-403 ≤175mg/kg
16 Recruiting Pilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas
Conditions: Ewing Sarcoma;   Osteosarcoma;   Rhabdomyosarcoma
Intervention: Biological: Expanded , Activated NK cells
17 Recruiting Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody
Conditions: Ewing Family of Tumors;   Melanoma;   Neuroblastoma;   Osteosarcoma
Intervention:
18 Recruiting A Study of IMRT in Primary Bone and Soft Tissue Sarcoma
Conditions: Soft Tissue Sarcoma, Adult;   Ewing Sarcoma;   Bone Sarcoma;   Chordoma
Intervention: Radiation: Intensity modulated radiotherapy (IMRT)
19 Recruiting Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma
Conditions: Osteosarcoma;   Ewing Sarcoma;   Rhabdomyosarcoma;   Soft Tissue Sarcoma
Interventions: Drug: nab-Paclitaxel;   Drug: Gemcitabine
20 Recruiting A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
Conditions: Ewing Sarcomas;   Chondrosarcomas;   Osteosarcomas;   Chondroma
Interventions: Drug: Regorafenib;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.